Picture of Spire Healthcare logo

SPI Spire Healthcare News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedMid CapNeutral

REG - Spire Healthcare Grp - Share Buyback Programme

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe3107Ka&default-theme=true

RNS Number : 3107K  Spire Healthcare Group PLC  31 October 2024

 

31 October 2024

 

Spire Healthcare Group plc

 

Share Buyback Programme

 

 

Spire Healthcare Group plc (LSE: SPI) ("Spire Healthcare" or "Company"), a
leading independent healthcare group in the United Kingdom, announces a return
of up to £5m cash to its shareholders through the means of an on-market share
buyback programme (the "Programme").

Spire Healthcare has entered into a non-discretionary arrangement with Numis
Securities Limited, trading as Deutsche Numis, to conduct the Programme on its
behalf commencing today, 31 October 2024, and ending no later than 31 December
2024. Under these arrangements, Deutsche Numis will conduct the repurchases of
the Company's ordinary shares of 1 pence each (the "Ordinary Shares") up to a
maximum aggregate consideration of £5m and will make trading decisions in
relation to the buyback of the Ordinary Shares within the programme terms and
pre-set parameters.

 

The sole purpose of the Programme is to reduce the issued share capital of the
Company, delivering further value for shareholders, and any Ordinary Shares
purchased under the Programme will be cancelled.

 

The Programme will be conducted by the Company in accordance with and under
the terms of the general authority granted by the Company's shareholders at
the Company's Annual General Meeting on 9 May 2024, pursuant to which the
Company has authority to purchase a maximum of 40,413,223 Ordinary Shares
(subject to certain limitations) (the "General Authority"). The aggregate
number of Ordinary Shares which may be acquired by the Company pursuant to the
Programme will not exceed the maximum number of Ordinary Shares which the
Company is authorised to purchase pursuant to the General Authority.

 

Any purchase of Ordinary Shares made in relation to the Programme will be
carried out on the London Stock Exchange. The buyback by Spire Healthcare will
be executed in accordance with Chapter 9 of the UK Listing Rules and the terms
of the General Authority. The Programme will be conducted within the
parameters prescribed by the Market Abuse Regulation (EU) 596/2014, the
Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK
domestic law by the European Union (Withdrawal) Act 2018) and with regard to
regulatory technical standards for the conditions applicable to buy-back
programmes and stabilisation measures.

 

Spire Healthcare will announce any purchase by it of Ordinary Shares no later
than 7.30 a.m. on the business day following the calendar day on which the
purchase occurs.

 

The Company will make further announcements in due course following the
completion of any repurchases. There is no guarantee that the Programme will
be implemented in full or that any Ordinary Shares will be repurchased by the
Company.

 

The Company confirms that it currently has no unpublished price sensitive
information.

 

- Ends -

 

For further information please contact:

 

Spire Healthcare

Harbant Samra, CFO
                        +44 (0)7881 672 365

 

Instinctif Partners

Julian
Walker
+44 (0)7825 189 696

 

Registered Office and Head Office:

 

Spire Healthcare Group plc

3 Dorset Rise

London

EC4Y 8EN

Registered number 09084066

 

About Spire Healthcare

 

Spire Healthcare (http://www.spirehealthcare.com/) is a leading independent
healthcare group in the United Kingdom, running 38 hospitals and over 50
clinics, medical centres and consulting rooms across England, Wales and
Scotland. It operates a network of private GPs and provides occupational
health services to over 800 corporate clients.

 

Working in partnership with over 8,600 experienced consultants, Spire
Healthcare delivered tailored, personalised care to over 1 million inpatients,
outpatients and daycase patients, and occupational health programme clients,
in 2023, and is the leading private provider, by volume, of knee
(https://www.spirehealthcare.com/treatments/bones-and-joints/knee-replacement/)
and hip
(https://www.spirehealthcare.com/treatments/bones-and-joints/hip-replacement-surgery/)
operations in the United Kingdom. It also delivers a range of private and NHS
mental health, musculoskeletal and dermatological services under the Vita
Health Group brand.

 

Spire Healthcare's well-located and scalable hospitals have delivered
successful and award-winning outcomes, positioning the group well with
patients, consultants, the NHS, GPs and Private Medical Insurance ('PMI')
providers. 98% of Spire Healthcare's inspected locations are rated 'Good',
'Outstanding' or the equivalent by health inspectors in England, Wales and
Scotland.

 

Spire Healthcare is listed on the London Stock Exchange and is a member of the
FTSE 250.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFDWFASELSELS

Recent news on Spire Healthcare

See all news